Literature DB >> 34606884

TSST-1+Staphylococcus aureus in Bullous Pemphigoid.

Kelly N Messingham1, Michael P Cahill2, Samuel H Kilgore2, Ananya Munjal3, Patrick M Schlievert2, Janet A Fairley3.   

Abstract

A potential role of Staphylococcus aureus in bullous pemphigoid was explored by examining the colonization rate in patients with new-onset disease compared with that in age- and sex-matched controls. S. aureus colonization was observed in 85% of bullous pemphigoid lesions, 3-6-fold higher than the nares or unaffected skin from the same patients (P ≤ 0.003) and 6-fold higher than the nares or skin of controls (P ≤ 0.0015). Furthermore, 96% of the lesional isolates produced the toxic shock syndrome toxin-1 superantigen, and most of these additionally exhibited homogeneous expression of the enterotoxin gene cluster toxins. Toxic shock syndrome toxin-1‒neutralizing antibodies were not protective against colonization. However, S. aureus colonization was not observed in patients who had recently received antibiotics, and the addition of antibiotics with staphylococcal coverage eliminated S. aureus and resulted in clinical improvement. This study shows that toxic shock syndrome toxin-1‒positive S. aureus is prevalent in bullous pemphigoid lesions and suggests that early implementation of antibiotics may be of benefit. Furthermore, our results suggest that S. aureus colonization could provide a source of infection in patients with bullous pemphigoid, particularly in the setting of high-dose immunosuppression.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34606884      PMCID: PMC9215375          DOI: 10.1016/j.jid.2021.08.438

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   7.590


  41 in total

1.  Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology.

Authors:  C Feliciani; P Joly; M F Jonkman; G Zambruno; D Zillikens; D Ioannides; C Kowalewski; H Jedlickova; S Kárpáti; B Marinovic; D Mimouni; S Uzun; S Yayli; M Hertl; L Borradori
Journal:  Br J Dermatol       Date:  2015-04       Impact factor: 9.302

Review 2.  Cytokines and bullous pemphigoid.

Authors:  L D'Auria; P Cordiali Fei; F Ameglio
Journal:  Eur Cytokine Netw       Date:  1999-06       Impact factor: 2.737

3.  Increased serum levels of interleukin (IL)-5, IL-6 and IL-8 in bullous pemphigoid.

Authors:  M Inaoki; K Takehara
Journal:  J Dermatol Sci       Date:  1998-01       Impact factor: 4.563

Review 4.  Complex host genetic susceptibility to Staphylococcus aureus infections.

Authors:  Sanjay K Shukla; Warren Rose; Steven J Schrodi
Journal:  Trends Microbiol       Date:  2015-06-22       Impact factor: 17.079

5.  Baclofen-Induced Dyshidrosiform Bullous Pemphigoid in a Paraplegic Patient Complicated by Methicillin-Resistant Staphylococcus aureus (MRSA) and Urinary Infection.

Authors:  Liborija Lugović-Mihić; Tomislav Duvančić; Ivana Pavić; Ana Gverić-Grginić; Mirna Šitum; Iva Dediol
Journal:  Acta Dermatovenerol Croat       Date:  2019-09       Impact factor: 1.256

6.  Prevalence estimates for pemphigoid in the United States: A sex-adjusted and age-adjusted population analysis.

Authors:  Sara Wertenteil; Amit Garg; Andrew Strunk; Allireza Alloo
Journal:  J Am Acad Dermatol       Date:  2018-08-28       Impact factor: 11.527

7.  Phenotypes and Virulence among Staphylococcus aureus USA100, USA200, USA300, USA400, and USA600 Clonal Lineages.

Authors:  Jessica M King; Katarina Kulhankova; Christopher S Stach; Bao G Vu; Wilmara Salgado-Pabón
Journal:  mSphere       Date:  2016-06-08       Impact factor: 4.389

8.  Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.

Authors:  Hywel C Williams; Fenella Wojnarowska; Gudula Kirtschig; James Mason; Thomas R Godec; Enno Schmidt; Joanne R Chalmers; Margaret Childs; Shernaz Walton; Karen Harman; Anna Chapman; Diane Whitham; Andrew J Nunn
Journal:  Lancet       Date:  2017-03-06       Impact factor: 79.321

9.  Staphylococcal Superantigens Stimulate Epithelial Cells through CD40 To Produce Chemokines.

Authors:  Patrick M Schlievert; Michael P Cahill; Bruce S Hostager; Amanda J Brosnahan; Aloysius J Klingelhutz; Francoise A Gourronc; Gail A Bishop; Donald Y M Leung
Journal:  mBio       Date:  2019-03-19       Impact factor: 7.867

10.  High Prevalence of Staphylococcus aureus Enterotoxin Gene Cluster Superantigens in Cystic Fibrosis Clinical Isolates.

Authors:  Anthony J Fischer; Samuel H Kilgore; Sachinkumar B Singh; Patrick D Allen; Alexis R Hansen; Dominique H Limoli; Patrick M Schlievert
Journal:  Genes (Basel)       Date:  2019-12-12       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.